Skip to main content

08-05-2019 | Urothelial cancer | News

News in brief

KEYNOTE-045: Pembrolizumab benefit maintained over 2 years in urothelial cancer


medwireNews: Patients with advanced urothelial cancer continue to derive a significant overall survival (OS) benefit with second-line pembrolizumab over chemotherapy, indicates an analysis of KEYNOTE-045 with more than 2 years of follow-up.

After a median follow-up of 27.7 months, the 1- and 2-year OS rates were 44.2% and 26.9% for the 270 patients who were randomly assigned to receive pembrolizumab 200 mg every 3 weeks after progressing on first-line platinum-based chemotherapy.

This was higher than the corresponding rates of 29.8% and 14.3% for their 272 counterparts who instead received investigator’s choice of paclitaxel, docetaxel, or vinflunine, and equated to a significant 30% reduction in the median risk for death with the PD-1 inhibitor.

As reported in Annals of Oncology, progression-free survival rates were also higher with pembrolizumab than chemotherapy, as was the objective response rate.

Of note, even “after this extended follow-up” the median duration of response was not reached in the pembrolizumab group (vs 4.4 months with chemotherapy), and the rates of any-grade (62.0 vs 90.6%) and grade 3 or worse (16.5 vs 50.2%) adverse events were lower, say the researchers.

And Yves Fradet (CHU de Québec-Université Laval, Québec City, Canada) and co-authors conclude that these “[l]ong-term results (>2 years’ follow-up) were consistent with those of previously reported analyses, demonstrating continued clinical benefit of pembrolizumab” in this patient population.

By Shreeya Nanda

 medwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group

Ann Oncol 2019: doi:10.1093/annonc/mdz127

See also: